Vectura Group plc

home / authors / vectura-group-plc

Articles

Control Strategies and Method Development for Nitrosamines in APIs and Drug Products

Biologic therapies: Charting the path from injectables to inhalation

Vectura Group plc

November 5th 2024

Webinar Date/Time: Thu, Nov 14, 2024 11:00 AM EST

Leveraging the Evolving Bioequivalence Regulatory Landscape to Enhance Product Design & Development

Vectura Group plc

July 10th 2024

Webinar Date/Time: Tue, Jul 30, 2024 11:00 AM EDT

Vectura – Helping You Succeed with Inhaled Product Development

Vectura Group plc

September 22nd 2020

Vectura helps customers bring inhaled medicines to market with a combination of formulation science, device technology, and inhaled product development expertise.

Dry Powder Inhalers: Key Considerations for Combination Product Development

Vectura Group plc

June 24th 2020

Dry powder inhalers (DPIs) are an important delivery technology for inhaled medicines in both respiratory and non-respiratory disease areas. Andreas Meliniotis, director of device development at Vectura, helps navigate the complex area of DPI product development and highlights the key considerations for both novel- and generic-drug programs. Live: Wednesday, Jun. 24, 2020 at 11am EDT |8am PDT |4pm BST |5pm CEST On demand available after final airing Jun. 24, 2021 Register free